The Cooral® System has recently been approved though a De Novo clearance by the U.S. Food and Drug Administration (FDA).
The market clearance paves the way for prevention of one of the most severe side-effects of chemotherapy, Oral Mucositis (OM). OM is a severely debilitating condition characterized by erythema and ulcerations of the oral mucosa (National Cancer Institute) .
The Cooral® System offers a solution to improve the quality of life for patients undergoing chemotherapy by providing medical professionals a proven method to reduce the risk of oral mucositis (OM).
The System includes a device that circulates cold, sterile water through a mouthpiece fitted to the patient. Cryotherapy (cold therapy) is administered and reduces blood flow to a targeted area. Consequently, metabolism is slowed which reduces the risk of developing OM.
![6257c1b75f68555f2e3b2c36_DO7I7159](https://braincoolinc.com/wp-content/uploads/2022/10/6257c1b75f68555f2e3b2c36_DO7I7159-200x300.jpg)
Improving quality of life
![DSC00376](https://braincoolinc.com/wp-content/uploads/2022/10/DSC00376-300x200.jpg)
More information can for now be found on http://www.coolprevent.com a sister company of BrainCool that handles our pain management product portfolio.